The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Covidien PLC

NYSE: COV
Last

(U.S.) $102.90

Today's change-0.32 -0.31%
Updated December 19 4:00 PM EST. Delayed by at least 15 minutes.
 

Covidien PLC

NYSE: COV
Last

(U.S.) $102.90

Today's change-0.32 -0.31%
Updated December 19 4:00 PM EST. Delayed by at least 15 minutes.

Covidien PLC down (U.S.)$0.32

Covidien PLC closed lower Friday, dropping (U.S.)$0.32 or 0.31% to (U.S.)$102.90. Over the last five days, shares have gained 2.40% and 51.10% year to date. Shares have outperformed the S&P 500 by 38.20% during the last year.

Key company metrics

  • Open(U.S.) $103.48
  • Previous close(U.S.) $103.22
  • High(U.S.) $103.89
  • Low(U.S.) $102.52
  • Bid / Ask-- / --
  • YTD % change+51.10%
  • Volume5,780,601
  • Average volume (10-day)3,354,665
  • Average volume (1-month)3,217,832
  • Average volume (3-month)5,013,727
  • 52-week range(U.S.) $65.97 to (U.S.) $103.90
  • Beta1.00
  • Trailing P/E28.20×
  • P/E 1 year forward23.78×
  • Forward PEG2.88×
  • Indicated annual dividend(U.S.) $1.44
  • Dividend yield1.40%
  • Trailing EPS(U.S.) $3.65
Updated December 19 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+15.59%

Based on its net profit margin of 15.59%, Covidien PLC is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.85%Sector:HealthcareIndustry:Medical Equipment, Supplies & Distribution
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q4/2014Q3/2014Q2/2014Q1/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 26, 201409/26/2014Jun 27, 201406/27/2014Mar 28, 201403/28/2014Dec 27, 201312/27/2013
Revenue2,7342,6882,5982,639
Total other revenue--------
Total revenue2,7342,6882,5982,639
Gross profit1,6621,5841,5181,563
Total cost of revenue1,0721,1041,0801,076
Total operating expense2,2212,3222,0162,108
Selling / general / administrative8801,030895868
Research & development149137135125
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)12347-9557
Other operating expenses, total--------
Operating income513366582531
Interest income (expense), net non-operating-49-48-54-53
Gain (loss) on sale of assets--------
Other--------
Income before tax401308601513
Income after tax517306441398
Income tax, total-1162160115
Net income517306441398
Total adjustments to net income--------
Net income before extra. items517306441398
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items517306441398
Inc. avail. to common incl. extra. items517306441398
Diluted net income520306441398
Dilution adjustment3------
Diluted weighted average shares459455454456
Diluted EPS excluding extraordinary itemsvalue per share1.130.670.970.87
Dividends per sharevalue per share0.680.000.640.00
Diluted normalized EPSvalue per share1.310.780.820.97